The BioInsights Podcast
Episodes
63 episodes
Exploring the landscape of novel targets & pathways in immuno-oncology
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O fi...
Multiomics integration: advancing pediatric cancer immunotherapy
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks with Raoul Santiago, Clinical Investigator and Associate Professor of Pediatric Hematology and Oncology, University Hospital Center, Laval University, to discuss the role of m...
Building with the patient in mind: designing a state-of-the-art facility for viral vector manufacturing
The cell and gene therapy space poses a number of unique challenges when it comes to facility design. In this episode, Róisin McGuigan, Editor, BioInsights, speaks to Yposkesi’s Louis-Marie De Montgrand and Morad El Gueddari
Can AAV continue to deliver the promise of gene therapy?
In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senio...
Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)
The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. In this episode, David McCall, Senior Editor, BioInsights, s...
Investing long-term in the cell & gene therapies of the future
David McCall, Senior Editor, BioInsights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital, about her VC company's portfolio of advanced therapy investments, and the keys to obtaining funding in a difficult environment. (From...
Happy medium: considerations in scaling cell culture media strategies
While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast,&n...
Applying multiomics to novel target discovery in immuno-oncology
In this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about...
Modernizing cell therapy manufacturing to reduce vein-to-vein times
Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.
Inducing innate immune responses with particulate adjuvants
Charlotte Barker, Editor, Vaccine Insights, speaks with Ed Lavelle, Professor, Trinity College Dublin, about our growing understanding of adjuvant mechanisms, his work on developing mucosal vaccines, and why size matters for nanopartic...
Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding...
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral? In this episode, Valeria Annibaldi and Andrea Toell discuss the types and benefits of non-viral methods for ex vivo cell and gene therapy in addit...
Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeutics
Cell therapy clinical trials pose a variety of complex challenges. Logistics with cell harvesting, manufacturing, shipments back to sites, patient safety, changing standard-of-care treatments, and patient enrolment due to competing trials can a...
Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturing
The tangential flow filtration (TFF) unit operation in viral vector manufacturing is a critical step on the path to commercialization. In this episode, Merck viral vector experts Ratish Krishnan and Akshat Gupta discuss best practices – and com...
Challenges in cryogenic storage containers for cell and gene therapy
Current options for cryogenic storage containers in cell and gene therapy are limited in their functionality as the industry continues to move towards increased scale and automation. In this episode, Sean Werner and Alex Sargent address spec...
Maximizing Efficiency and Flexibility in Viral Vector Manufacturing Scale-up
Four viral vector experts from diverse groups within Pall Corporation’s gene therapy manufacturing organization – Denis Kole, Jon Petrone, Marc Bisschops and Nathan Hazi – join BioInsights to share insights in hot topics for the field, includin...
Improvement of viral vector purification using Mustang Q membrane chromatography
Saadia Zakai and Mark Schofield of Pall join Hélène Lebas of leading viral vector CDMO, Yposkesi, to discuss key current trends and challenges in AAV and lentiviral vector manufacturing, with a particular focus on the cutting edge in lentiviral...
Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturing
The tangential flow filtration (TFF) unit operation in viral vector manufacturing is a critical step on the path to commercialization. In this episode, Merck viral vector experts Ratish Krishnan and Akshat Gupta discuss best practices – and com...
CAR-T cells: from cancer to autoimmunity
Professor Dimitrios Mougiakakos is the director of the Hematology and Oncology department at the Otto-von-Guericke University in Magdeburg, Germany. In this episode, he joins us to discuss the exciting potential for CAR T cell therapy for autoi...
Tales, tips & teachable moments from applications support veterans
Cell and gene therapy scientists are under increasing pressure to achieve results faster and produce cells and cell products more cost-efficiently. Field applications scientists from their major suppliers can provide invaluable support, helping...
Access to vaccines: how can we leverage technology innovations to achieve greater vaccine equity?
Fatema Kazi works for the WHO, where she helps to assess the public health value of vaccine products and technologies in routine, campaign, and outbreak settings. We caught up with her to discuss how innovations in vaccine technology can help g...
De-risk & accelerate the drug development process for gene therapy
In today’s challenging financial environment, it is more important than ever to get key biotech business decisions right first time. One of the most important and topical of these is the choice of CDMO partner. Dr Kim Watanabe, General Manager ...
Working Together to Safely Advance Cell & Gene Therapies
Drug development is a costly and time-consuming process associated with a significant attrition rate in the clinic. Safety is an important factor in this, and is a particular issue for cell and gene therapies. A panel moderated by Dr John Maher...
Learning from pediatric CAR-T development: insights from manufacturing unique patient doses
What valuable experiences from first generation cell therapies can the industry carry forward and apply to other indications, such as solid tumors? In this episode, Sean Werner and Chris Brown explore the most important lessons the industry has...
Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us
Tom Foti (Vice President and General Manager of the Protein Business Unit, Aldevron) and Dr Kris Saha (Associate Professor of Biomedical Engineering and Medical History and Bioethics, University of Wisconsin-Madison) discuss ongoing work in Dr ...